286 related articles for article (PubMed ID: 28422710)
1. The role of metabolic tumor volume (MTV) measured by [18F] FDG PET/CT in predicting EGFR gene mutation status in non-small cell lung cancer.
Liu A; Han A; Zhu H; Ma L; Huang Y; Li M; Jin F; Yang Q; Yu J
Oncotarget; 2017 May; 8(20):33736-33744. PubMed ID: 28422710
[TBL] [Abstract][Full Text] [Related]
2. Measurement of tumor volume by PET to evaluate prognosis in patients with advanced non-small cell lung cancer treated by non-surgical therapy.
Yan H; Wang R; Zhao F; Zhu K; Jiang S; Zhao W; Feng R
Acta Radiol; 2011 Jul; 52(6):646-50. PubMed ID: 21508201
[TBL] [Abstract][Full Text] [Related]
3. Role of 18F-fluorodeoxyglucose positron emission tomography in predicting epidermal growth factor receptor mutations in non-small cell lung cancer.
Mak RH; Digumarthy SR; Muzikansky A; Engelman JA; Shepard JA; Choi NC; Sequist LV
Oncologist; 2011; 16(3):319-26. PubMed ID: 21339258
[TBL] [Abstract][Full Text] [Related]
4. Metabolic tumor burden as marker of outcome in advanced EGFR wild-type NSCLC patients treated with erlotinib.
Winther-Larsen A; Fledelius J; Sorensen BS; Meldgaard P
Lung Cancer; 2016 Apr; 94():81-7. PubMed ID: 26973211
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography-derived metabolic parameters in surgically resected clinical-N0 nonsmall cell lung cancer.
Aktas GE; Karamustafaoğlu YA; Balta C; Süt N; Sarikaya İ; Sarikaya A
Nucl Med Commun; 2018 Nov; 39(11):995-1004. PubMed ID: 30188416
[TBL] [Abstract][Full Text] [Related]
6. [Value of (18)F-FDG PET-CT imaging to predict epidermal growth factor receptor mutations in patients with lung squamous cell carcinoma].
Zhao CY; Deng XY; Wang HS; Cao GP; Ding JN; Ding CY
Zhonghua Zhong Liu Za Zhi; 2021 Jul; 43(7):795-800. PubMed ID: 34289575
[No Abstract] [Full Text] [Related]
7. FDG uptake in non-small cell lung cancer is not an independent predictor of EGFR or KRAS mutation status: a retrospective analysis of 206 patients.
Lee SM; Bae SK; Jung SJ; Kim CK
Clin Nucl Med; 2015 Dec; 40(12):950-8. PubMed ID: 26359571
[TBL] [Abstract][Full Text] [Related]
8. [Evaluate the value of (18)F-FDG PET-CT imaging in predicting the mutationsin epidermal growth factor receptor in lung adenocarcinoma].
Ding CY; Yang WP; Guo Z; Sun J; Li YY; Li TR
Zhonghua Zhong Liu Za Zhi; 2017 Jul; 39(7):528-531. PubMed ID: 28728300
[No Abstract] [Full Text] [Related]
9. 18F-FDG uptake for prediction EGFR mutation status in non-small cell lung cancer.
Guan J; Xiao NJ; Chen M; Zhou WL; Zhang YW; Wang S; Dai YM; Li L; Zhang Y; Li QY; Li XZ; Yang M; Wu HB; Chen LH; Liu LY
Medicine (Baltimore); 2016 Jul; 95(30):e4421. PubMed ID: 27472739
[TBL] [Abstract][Full Text] [Related]
10. Total metabolic tumor volume by 18F-FDG PET/CT for the prediction of outcome in patients with non-small cell lung cancer.
Pellegrino S; Fonti R; Mazziotti E; Piccin L; Mozzillo E; Damiano V; Matano E; De Placido S; Del Vecchio S
Ann Nucl Med; 2019 Dec; 33(12):937-944. PubMed ID: 31612416
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
[TBL] [Abstract][Full Text] [Related]
12. Role of [¹⁸F]FDG PET in prediction of KRAS and EGFR mutation status in patients with advanced non-small-cell lung cancer.
Caicedo C; Garcia-Velloso MJ; Lozano MD; Labiano T; Vigil Diaz C; Lopez-Picazo JM; Gurpide A; Zulueta JJ; Richter Echevarria JA; Perez Gracia JL
Eur J Nucl Med Mol Imaging; 2014 Nov; 41(11):2058-65. PubMed ID: 24990403
[TBL] [Abstract][Full Text] [Related]
13. Volume-based parameters of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography improve outcome prediction in early-stage non-small cell lung cancer after surgical resection.
Hyun SH; Choi JY; Kim K; Kim J; Shim YM; Um SW; Kim H; Lee KH; Kim BT
Ann Surg; 2013 Feb; 257(2):364-70. PubMed ID: 22968069
[TBL] [Abstract][Full Text] [Related]
14. Value of
Lv Z; Fan J; Xu J; Wu F; Huang Q; Guo M; Liao T; Liu S; Lan X; Liao S; Geng W; Jin Y
Eur J Nucl Med Mol Imaging; 2018 May; 45(5):735-750. PubMed ID: 29164298
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of metabolic tumor volume of pretreatment
Kumasaka S; Nakajima T; Arisaka Y; Tokue A; Achmad A; Fukushima Y; Shimizu K; Kaira K; Higuchi T; Tsushima Y
BMC Med Imaging; 2018 Nov; 18(1):46. PubMed ID: 30477476
[TBL] [Abstract][Full Text] [Related]
16. Utility of Volumetric Metabolic Parameters on Preoperative FDG PET/CT for Predicting Tumor Lymphovascular Invasion in Non-Small Cell Lung Cancer.
Li C; Tian Y; Shen Y; Wen B; He Y
AJR Am J Roentgenol; 2021 Dec; 217(6):1433-1443. PubMed ID: 33978465
[No Abstract] [Full Text] [Related]
17. Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer.
Chen HH; Chiu NT; Su WC; Guo HR; Lee BF
Radiology; 2012 Aug; 264(2):559-66. PubMed ID: 22692034
[TBL] [Abstract][Full Text] [Related]
18. Standardized uptake value on (18)F-FDG-PET/CT is a predictor of EGFR T790M mutation status in patients with acquired resistance to EGFR-TKIs.
Yoshida T; Tanaka H; Kuroda H; Shimizu J; Horio Y; Sakao Y; Inaba Y; Iwata H; Hida T; Yatabe Y
Lung Cancer; 2016 Oct; 100():14-19. PubMed ID: 27597275
[TBL] [Abstract][Full Text] [Related]
19. The value of different
Anwar H; Vogl TJ; Abougabal MA; Grünwald F; Kleine P; Elrefaie S; Nour-Eldin NA
Ann Nucl Med; 2018 Dec; 32(10):687-694. PubMed ID: 30219989
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of Amide Proton Transfer-Weighted Imaging for Lung Cancer Subtype and Epidermal Growth Factor Receptor: A Comparative Study With Diffusion and Metabolic Parameters.
Meng N; Fu F; Feng P; Li Z; Gao H; Wu Y; Zhang J; Wei W; Yuan J; Yang Y; Liu H; Cheng J; Wang M
J Magn Reson Imaging; 2022 Oct; 56(4):1118-1129. PubMed ID: 35258145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
